Might existing drugs (including olamkicept or sodium–glucose cotransporter 2 (SGLT-2) inhibitors) prove useful as anti-arrhythmic drugs if we can demonstrate that specific targets might be key mediators of obesity-related malignant VT? The gene discussed is SLC5A2; the disease is obesity disorder.